Annabel Samimy Analyst Performance

Annabel Samimy is a stock analyst at Stifel Nicolaus in the medical sector, covering 11 publicly traded companies. Over the past year, Annabel Samimy has issued 3 stock ratings, including and buy recommendations. While full access to Annabel Samimy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Annabel Samimy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

32 Last 10 Years

Buy Recommendations

83.33% 25 Buy Ratings

Companies Covered

11 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	83.3%	25 ratings
Hold	16.7%	5 ratings
Sell	0.0%	0 ratings

Out of 30 total stock ratings issued by Annabel Samimy at Stifel Nicolaus, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  TXMD

  Apr 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  PHAS

  Oct 2021

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	72.7% of companies on NASDAQ	8 companies
NYSE	27.3% of companies on NYSE	3 companies

Annabel Samimy, an analyst at Stifel Nicolaus, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 11 companies	100.0%

Annabel Samimy of Stifel Nicolaus specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
PHARMACEUTICAL PREPARATIONS 4 companies	36.4%
MED - BIOMED/GENE 2 companies	18.2%
MED - GENERIC DRG 2 companies	18.2%
MED PRODUCTS 2 companies	18.2%
MED - DRUGS 1 company	9.1%

Annabel Samimy's Ratings History at Stifel Nicolaus

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
PVLA Palvella Therapeutics	9/24/2025	Boost Price Target	$59.95	$80.00	Buy	$0.00 00.00% ROI
LGND Ligand Pharmaceuticals	4/10/2025	Initiated Coverage	$103.85	$143.00	Buy	$0.00 00.00% ROI
PVLA Palvella Therapeutics	3/26/2025	Initiated Coverage	$27.27	$45.00	Buy	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.